ATAI Life Sciences

IntelGenX is an oral drug delivery company that specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm technology platform. The company focuses on creating novel immediate-release and controlled-release products for the pharmaceutical market. It offers a wide range of services to its partners, including research and development, analytical method development, clinical monitoring, intellectual property support, and regulatory assistance. IntelGenX operates a state-of-the-art manufacturing facility that accommodates lab-scale, pilot, and commercial-scale production, providing full-service capabilities to its clients. The company primarily generates revenue from Europe, while also serving markets in Canada and the United States.

Beckley Psytech Limited is a company based in Oxford, United Kingdom, that specializes in developing psychedelic drugs aimed at treating psychiatric and neurological diseases. Founded in 2014, the company explores the therapeutic potential of substances such as psilocybin to address mental health issues, including depression and other debilitating neuropsychiatric conditions. Beckley Psytech is focused on integrating clinically validated psychedelic medicines into contemporary medical practices, providing alternative treatments for patients who have significant unmet needs. Through its drug pipeline, the company aims to innovate and differentiate its offerings in the marketplace, enhancing options for individuals suffering from these disorders.

Beckley Psytech Limited is a company based in Oxford, United Kingdom, that specializes in developing psychedelic drugs aimed at treating psychiatric and neurological diseases. Founded in 2014, the company explores the therapeutic potential of substances such as psilocybin to address mental health issues, including depression and other debilitating neuropsychiatric conditions. Beckley Psytech is focused on integrating clinically validated psychedelic medicines into contemporary medical practices, providing alternative treatments for patients who have significant unmet needs. Through its drug pipeline, the company aims to innovate and differentiate its offerings in the marketplace, enhancing options for individuals suffering from these disorders.

IntelGenX is an oral drug delivery company that specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm technology platform. The company focuses on creating novel immediate-release and controlled-release products for the pharmaceutical market. It offers a wide range of services to its partners, including research and development, analytical method development, clinical monitoring, intellectual property support, and regulatory assistance. IntelGenX operates a state-of-the-art manufacturing facility that accommodates lab-scale, pilot, and commercial-scale production, providing full-service capabilities to its clients. The company primarily generates revenue from Europe, while also serving markets in Canada and the United States.

IntelGenX is an oral drug delivery company that specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm technology platform. The company focuses on creating novel immediate-release and controlled-release products for the pharmaceutical market. It offers a wide range of services to its partners, including research and development, analytical method development, clinical monitoring, intellectual property support, and regulatory assistance. IntelGenX operates a state-of-the-art manufacturing facility that accommodates lab-scale, pilot, and commercial-scale production, providing full-service capabilities to its clients. The company primarily generates revenue from Europe, while also serving markets in Canada and the United States.

IntelGenX is an oral drug delivery company that specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm technology platform. The company focuses on creating novel immediate-release and controlled-release products for the pharmaceutical market. It offers a wide range of services to its partners, including research and development, analytical method development, clinical monitoring, intellectual property support, and regulatory assistance. IntelGenX operates a state-of-the-art manufacturing facility that accommodates lab-scale, pilot, and commercial-scale production, providing full-service capabilities to its clients. The company primarily generates revenue from Europe, while also serving markets in Canada and the United States.

Psyber is a company focused on developing interventions for mental health disorders through brain-computer interface (BCI)-enabled digital therapeutics. By integrating BCI technology with psychedelics, Psyber creates therapeutic devices that monitor electrical activity in the brain, allowing for real-time interpretation of emotional, behavioral, and mental states. This innovative approach empowers patients who are prescribed medication, enabling them to modify their feelings and behaviors. Ultimately, Psyber aims to enhance the quality of life for individuals facing mental health challenges through advanced digital health solutions.

IntelGenX is an oral drug delivery company that specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm technology platform. The company focuses on creating novel immediate-release and controlled-release products for the pharmaceutical market. It offers a wide range of services to its partners, including research and development, analytical method development, clinical monitoring, intellectual property support, and regulatory assistance. IntelGenX operates a state-of-the-art manufacturing facility that accommodates lab-scale, pilot, and commercial-scale production, providing full-service capabilities to its clients. The company primarily generates revenue from Europe, while also serving markets in Canada and the United States.

IntelGenX is an oral drug delivery company that specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm technology platform. The company focuses on creating novel immediate-release and controlled-release products for the pharmaceutical market. It offers a wide range of services to its partners, including research and development, analytical method development, clinical monitoring, intellectual property support, and regulatory assistance. IntelGenX operates a state-of-the-art manufacturing facility that accommodates lab-scale, pilot, and commercial-scale production, providing full-service capabilities to its clients. The company primarily generates revenue from Europe, while also serving markets in Canada and the United States.

Recognify Life Sciences is a biotechnology company focused on developing innovative treatments for cognitive impairment related to schizophrenia. The company is engaged in creating pharmaceutical therapies that aim to modulate the excitatory and inhibitory balance in the brain, which is essential for enhancing learning and memory. By addressing cognitive impairment, Recognify Life Sciences seeks to provide healthcare providers with effective treatment options for not only schizophrenia but also Alzheimer's and other neurodegenerative and neurocognitive diseases.

COMPASS Pathways plc is a mental health care company based in the United Kingdom and the United States, focusing on developing innovative therapies for treatment-resistant depression. The company is conducting Phase IIb clinical trials for its psilocybin formulation, COMP360, which aims to provide a new treatment option for patients who have not responded to conventional therapies. By researching psilocybin-assisted therapy, COMPASS Pathways seeks to assess its safety and efficacy, while combining the psychedelic compound with psychological support. The company was incorporated in 2020 and aims to address the significant unmet need for effective and accessible mental health treatments, striving to empower individuals facing mental health challenges.

At INNOPLEXUS we are helping organisations move to continuous decision-making by generating broader, deeper and faster insights from structured and unstructured private and public data leveraging cutting-edge, patented Artificial Intelligence, Blockchain and advanced analytics technologies. We aim to transform batch decision making in enterprises into a empowered, inspired and faster continuum. We focus on industries that need to constantly evaluate and improve their efficiency, reduce cost and mitigate risk to keep up with the changing business environment - like global banking, life sciences, and pharmaceutical companies. In addition to strengthening research efforts, we work to help healthcare organizations leverage technologies to expedite drug development process across all stages - preclinical, clinical, regulatory and commercial. Whether a drug developer is seeking existing research, a medical researcher is searching for alternative treatments, or a practitioner is attempting to find data on a particular disease - increasing access to relevant information removes roadblocks to discovery and fuels rapid growth. Our Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions are helping Fortune 500 companies drive business outcomes. We automate the collection, curation, aggregation and analysis, of billions of data points from thousands of data sources, using machine learning, network analysis, ontologies, computer vision and entity normalization. Founded in 2015, INNOPLEXUS AG is headquartered in Eschborn Germany with offices in Pune, India, and Hoboken, USA.

Perception Neuroscience is a biopharmaceutical company dedicated to creating innovative therapies for neuropsychiatric disorders. The company is primarily focused on developing arketamine, an NMDA antagonist that aims to offer effective treatment solutions for serious psychiatric conditions. Arketamine is designed to provide rapid-acting antidepressant effects and has the potential to reduce suicidal ideation, addressing a critical need in mental health care. Through its research and development efforts, Perception Neuroscience seeks to improve outcomes for patients suffering from challenging psychiatric illnesses.